Development and testing of a mobile application to enhance HIV prevention cascade in Malaysian MSM

开发和测试移动应用程序，以加强马来西亚男男性接触者的艾滋病毒预防级联

• 批准号: 10064800
• 负责人: Roman Shrestha
• 金额: $ 0.87万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-11 至 2020-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10064800
• 关键词: AIDS prevention; Achievement; Acquired Immunodeficiency Syndrome; Address; Adherence; Alcohol or Other Drugs use; Amphetamines; Asia; Benchmarking; Caring; Cellular Phone; Client; Clinic; Communication; Counseling; Country; Decision Making; Development; Discrimination; Drug usage; Epidemic; Face; Focus Groups; Fright; Guide prevention; HIV; HIV Infections; Health; Health Personnel; Health Professional; Health Services; Health Technology; Healthcare; Homosexuality; Human immunodeficiency virus test; Hybrids; Incidence; Income; Institution; Intervention; Interview; Laws; Learning; Link; Malaysia; Malaysian; Measures; Mental Depression; Mental Health; Mental disorders; Modeling; Motivation; Muslim population group; Outcome; Patients; Persons; Phase; Population; Prevalence; Prevention; Preventive Intervention; Provider; Psyche structure; Psychotic Disorders; Readiness; Research; Research Personnel; Risk; Risk Behaviors; Services; Sexual Health; Sexual Transmission; Sexuality; Sexually Transmitted Diseases; Statutes and Laws; Stigmatization; Strategic Planning; Study models; Substance Use Disorder; Suicide; Technology; Testing; Translating; Universities; Unsafe Sex; Ursidae Family; base; care systems; clinical care; comorbidity; cost effective; depressive symptoms; design; efficacy testing; evidence base; health care delivery; health disparity; health management; high risk; implementation science; improved; innovation; insight; interest; low and middle-income countries; mHealth; men; men who have sex with men; mobile application; mortality; overtreatment; pre-exposure prophylaxis; preference; prevention service; prospective test; prototype; research and development; response; scale up; screening; sex; social stigma; southeast Asian; stimulant use; treatment as usual; uptake; usability; virtual

Abstract Malaysia’s HIV epidemic is rapidly expanding with recent evidence suggesting accelerated sexual transmission, especially in MSM: 10% in 2008 to 54% in 2016. Evidence suggests high HIV prevalence in MSM being nationally (21.6%) and in Kuala Lumpur (43%). Central to this expanding HIV epidemic in MSM is condomless sex, STIs, and co-occurring psychiatric and substance use disorders (P/SUD), especially depression and amphetamine-type stimulant (ATS) use. Insights into Malaysia’s HIV prevention gap are multi-factorial. Both homosexuality and substance use is criminalized in Malaysia, making MSM bear the dual burden of stigma and discrimination, including in healthcare, which promotes P/SUD disparities in MSM. MSM are often hesitant to disclose their sexuality, risk behaviors or depressive symptoms, mostly due to fear of stigma, discrimination, or criminalization. Stigma and discrimination are also enacted on MSM by healthcare providers resulting in extraordinary health disparities and low prevention uptake. Strategies that facilitate screening and prevention practices in a non-judgmental fashion are likely to increase access to evidence-based prevention like HIV testing and pre-exposure prophylaxis (PrEP), especially if screening and counseling addresses P/SUD. Introducing an innovative app-based platform to deliver holistic HIV prevention services represents a paradigm shift in HIV prevention since it can deliver effective prevention in a confidential, less-stigmatizing and convenient manner. Building on the advantages for scalability and dissemination afforded using app platform, we propose to develop and test the efficacy of a clinic-affiliated app (myCareLink) to deliver an integrated HIV prevention intervention that will promote HIV testing and linkage to PrEP and incorporates screening and support for underlying P/SUD in Malaysian MSM. The design of this study will take place in 2 phases. The R21 phase will consist of 2 stages: 1) We will adapt, expand and refine an existing app, which will be integrated within the existing clinical care system. First, we will conduct focus groups with MSM (n=25) and stakeholders (n=10) to theater test the existing app to develop an interactive prototype of the myCareLink app (alpha version). Then, the prototype will undergo usability testing (n=20), followed by the full development of the app (beta version); 2) Expanded Beta testing (n=50) of the myCareLink app will assess its usability and acceptability. The R33 phase will involve conducting a Type 1 Hybrid Implementation Science Trial to evaluate the efficacy of myCareLink app vs. treatment as usual (TAU) in 268 Malaysian MSM for primary (HIV testing and PrEP uptake) and secondary (PrEP adherence and persistence) efficacy outcomes. Multi-level implementation outcomes will involve stakeholders’ perspective of the relative advantage of myCareLink app over TAU, adaptability, perceived design quality and packaging, compatibility in the Malaysian context, interest in sharing the app with others and readiness for implementation. Research capacity strengthening between Yale and the University of Malaya will occur through collaborative learning between researchers at both institutions to promote expansion of mHealth research.

抽象的 马来西亚的艾滋病毒流行正在迅速扩大，最近的证据表明性行为加速 传播率，特别是在男男性行为者中：2008 年为 10%，2016 年为 54%。有证据表明，男男性行为者中艾滋病毒感染率很高 全国（21.6%）和吉隆坡（43%）是 MSM 中艾滋病毒流行的核心。 无套性行为、性传播感染以及同时发生的精神和物质使用障碍 (P/SUD)，尤其是抑郁症 和安非他明类兴奋剂 (ATS) 的使用 对马来西亚艾滋病毒预防差距的深入了解是多方面的。 同性恋和药物滥用在马来西亚都被定为犯罪，使男男性行为者承受着耻辱的双重负担 歧视（包括医疗保健领域的歧视）会导致 MSM 中的 P/SUD 差异，而 MSM 往往会犹豫不决。 披露自己的性取向、危险行为或抑郁症状，主要是因为害怕耻辱、歧视， 医疗保健提供者也对男男性行为者进行污名化和歧视，从而导致 巨大的健康差异和促进筛查和预防的预防策略的采用率较低。 以非评判方式进行的做法可能会增加获得艾滋病毒检测等循证预防的机会 暴露前预防 (PrEP)，特别是在筛查和咨询解决 P/SUD 的情况下。 基于应用程序的创新平台提供全面的艾滋病毒预防服务，代表着艾滋病毒领域的范式转变 预防，因为它可以以保密、减少污名化和便捷的方式提供有效的预防。 利用应用程序平台提供的可扩展性和传播优势，我们建议开发 并测试诊所附属应用程序 (myCareLink) 提供综合艾滋病毒预防干预措施的功效 这将促进 HIV 检测和与 PrEP 的联系，并纳入对基础 P/SUD 的筛查和支持 这项研究的设计将分两个阶段进行。R21 阶段将包括 2 个阶段：1) 我们将调整、扩展和完善现有的应用程序，并将其集成到现有的临床护理系统中。 首先，我们将与 MSM (n=25) 和利益相关者 (n=10) 进行焦点小组测试，以对现有应用程序进行测试 开发 myCareLink 应用程序的交互式原型（alpha 版本） 然后，原型将进行。 可用性测试（n=20），然后是应用程序的完整开发（测试版）2) 扩展 Beta 测试； myCareLink 应用程序的 (n=50) 将评估其可用性和可接受性 R33 阶段将涉及进行。 1 型混合实施科学试验，用于评估 myCareLink 应用程序与常规治疗的疗效 (TAU) 在 268 名马来西亚 MSM 中进行初级（HIV 检测和 PrEP 摄取）和次级（PrEP 依从性和 多层次的实施结果将涉及利益相关者的观点。 myCareLink 应用程序相对于 TAU 的相对优势、适应性、感知设计质量和包装， 马来西亚环境的兼容性、与他人共享应用程序的兴趣以及实施的准备。 耶鲁大学和马来亚大学之间的研究能力将通过合作加强 两个机构的研究人员之间相互学习，以促进移动医疗研究的扩展。